Shin-pei Tsay talks about protecting driver's flexibility.
Shin-pei Tsay talks about protecting driver's flexibility.
American Express (NYSE: AXP) and Uber today announced an exclusive new offer for U.S. Consumer Platinum, Gold and Green Card Members and an Uber Cash benefit for Gold Card Members to bring their next at-home dining experience right to their doorstep and support the local restaurants in their communities.
Dr. Anthony Fauci, the nation’s top infectious disease expert, joined Yahoo Finance's All Markets Summit to discuss what phase of the novel coronavirus the United States is now in.
The Democratic leaders of two U.S. House of Representatives Committees said on Monday the Office of Special Counsel had launched an investigation of Secretary of State Mike Pompeo's speech to the Republican National Convention in August. Pompeo, who was appointed to his position by President Donald Trump, praised the Republican president's foreign policy record in a speech recorded in Jerusalem in August during a trip to Israel. "Our offices have confirmed that the Office of Special Counsel has launched a probe into potential Hatch Act violations tied to Secretary Pompeo’s speech to the Republican National Convention" Representatives Nita Lowey, who chairs the House Appropriations Committee, and Eliot Engel, leader of House Foreign Affairs, said in a joint statement.
With home prices rising and foreclosure moratoriums in place across the country, finding a great deal has gotten harder than ever -- especially in some bigger markets. Nationally, home prices were up 14.8% year over year in September, according to the National Association of Realtors (NAR). According to CoreLogic’s (NYSE: CLGX) recent data, there are five markets where home prices will very likely drop (think 70% chance or more) in the next year.
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Baxter Healthcare to supply pre-filled, single-use IV bags of dexmedetomidine hydrochloride to healthcare providers, helping to stabilize the long-term supply of a medication needed to care for some of the most acute cases of COVID-19.
Fabric Genomics announces a co-marketing agreement that will provide translational researchers with integrated sample prep to reporting workflows.
NetApp announces new serverless & storageless solution for containers, an autonomous hybrid cloud platform and virtual desktop solutions at INSIGHT.
IP Infusion introduces Universal SD-Edge solution to offer next generation of uCPE solutions at the WAN Edge
Humana’s Medicare Advantage Network Expands in Grand Junction and Fruita with Addition of Primary Care Partners
The Global Sexual Enhancement Supplements Market will grow by $ 407.16 mn during 2020-2024
Wabtec Corporation (NYSE: WAB) released today its 2020 Sustainability Report, which highlights the company’s accomplishments and commitments to building a more sustainable future by developing innovative technologies, driving responsible operations, and empowering people and communities around the globe. The report can be found here.
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few...
MIDDLETOWN, R.I., Oct. 26, 2020 (GLOBE NEWSWIRE) -- KVH Industries, Inc., (Nasdaq: KVHI), will announce its financial results for the third quarter that ended September 30, 2020, on Thursday, October 29, 2020. In conjunction with the release, the company will conduct its investor conference call at 9:00 a.m. ET, hosted by Mr. Martin Kits van Heyningen, chief executive officer, Mr. Donald Reilly, chief financial officer, and Mr. Brent Bruun, chief operating officer. A live broadcast of the call will be available online at investors.kvh.com. In addition, an audio replay of the conference call will be available on the website for at least two weeks. To listen to the replay, visit investors.kvh.com starting three hours following the conclusion of the call. Investors who wish to submit questions during or following the call may do so to IR@kvh.com.About KVH Industries, Inc.KVH Industries is a global leader in mobile connectivity and inertial navigation systems, innovating to enable a mobile world. The market leader in maritime VSAT, KVH designs, manufactures, and provides connectivity and content services globally. KVH is also a premier manufacturer of high-performance sensors and integrated inertial systems for defense and commercial applications. Founded in 1982, the company is based in Middletown, RI, with research, development, and manufacturing operations in Middletown, RI, and Tinley Park, IL, and more than a dozen offices around the globe.Contact:Jill Connors Sr. Manager, Media & Industry Analyst Relations KVH Industries, Inc. 401-851-3824 firstname.lastname@example.org
Felicien Kabuga, suspected of financing the 1994 Rwandan genocide, has been moved from France to The Hague ahead of his trial, a UN tribunal said Monday.
USAMRIID researchers to test Vaxil’s CorVax™ (signal peptides) that may lead to a successful COVID-19 vaccineNOT FOR DISTRIBUTION BY US NEWSWIRE OR IN UNITED STATESNESS-ZIONA, Israel, Oct. 26, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that on October 26, 2020, it has entered into a cooperative research and development agreement (CRADA) with USAMRIID under which USAMRIID will test CorVax™ for its ability to specifically prevent COVID-19 in mice.Vaxil recently reported that its CorVax™ successfully generated an immune response in the experiment carried out at the Allergy and Clinical Immunology Unit at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel by Dr. David Hagin. As a result, the Company is progressing to the next study to test whether this immune response is specific enough to COVID-19 to provide protection against the virus in a mouse model.As scientists and companies race to find vaccines to prevent COVID-19 infection, some platforms are focused on mRNA, others on viral vectors, viruses and various subunits. Vaxil is, to the best of the Company’s knowledge, the only company working with signal peptides, which offer unique advantages of efficacy in stimulating a broad immune response while achieving a suitable safety profile. Vaxil’s signal peptide platform has proven safety in a phase 1/2a study in oncology.“The initial immunogenicity data sound intriguing,” said Dr. Joseph W. Golden, a principal investigator in USAMRIID’s virology division. “We look forward to evaluating this vaccine formulation for its potential to protect against SARS-CoV-2 in our mouse models.”The work to be performed by USAMRIID will be financed out of the Company’s existing working capital, according to David Goren, Vaxil’s Chairman and Chief Executive Officer. The team hopes to secure additional funding for future studies.“We are pleased to have USAMRIID assess our potential COVID-19 vaccine,” said Goren. “The work in the US will support and strengthen the experiments we have already done in Israel in our in-vivo study. Together, the combined research will help the Company plan and execute more efficient pre-clinical and clinical programs.”The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.ABOUT VAXILVaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.About the U.S. Army Medical Research Institute of Infectious DiseasesFor over 50 years, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutions - vaccines, drugs, diagnostics, information, and training programs - that benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Development Command. For more information, visit http://www.usamriid.army.mil.[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.]CONTACT INFORMATION For further information please visit http://vaxil-bio.com/ or contact: David Goren, CEO -- email@example.com, +972 (52) 720-6000
Would-be owners may want to look past the headlines and think about the sort of numbers that may (or may not) be at stake.
French authorities are looking at a range of options for the further tightening of restrictions to try to contain the spread of COVID-19 infection, according to three sources familiar with the government's thinking. France two weeks ago imposed a curfew that runs from 9:00 pm (1900 GMT) to 6:00 am every day, giving it some of the strictest restrictions in Europe, but since then new confirmed cases and hospitalisations have kept climbing. Two industry sources in contact with the government said measures being looked at by officials included moving the start of the curfew forward to earlier in the evening, confining people to their homes at weekends except for essential trips, and the closure of non-essential shops.
Land O' Lakes CEO Beth Ford has made it her mission to get farmers connected and close the digital divide.
US President Donald Trump denied Monday that he is giving up on fighting the spread of the coronavirus, insisting, despite a new surge in infections, that the pandemic is in retreat.
A third attempt at halting weeks of fighting over Nagorno-Karabakh collapsed quickly on Monday with Armenia and Azerbaijan trading accusations of violating the US-brokered ceasefire within minutes.